Stem cell transplant for Waldenström macroglobulinemia

An underutilized technique

Morie Gertz, C. B. Reeder, R. A. Kyle, Stephen Maxted Ansell

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Waldenström macroglobulinemia is a highly chemosensitive lymphoplasmacytic lymphoma with response rates of 90% to first-line chemotherapy. The fraction of patients undergoing stem cell transplant for this disorder appears to be lower than that of patients with multiple myeloma. The indolent nature and favorable genetic profile should make Waldenström an ideal disorder for autologous stem cell transplant, with high response rates that are durable. We review the literature on autologous and allogeneic transplants for Waldenström macroglobulinemia and conclude that autologous transplant is effective and underutilized in the management of this disorder. Allogeneic transplant should be considered investigational and used only in the context of a clinical trial or when other chemotherapeutic options have been exhausted.

Original languageEnglish (US)
Pages (from-to)1147-1153
Number of pages7
JournalBone Marrow Transplantation
Volume47
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

Waldenstrom Macroglobulinemia
Stem Cells
Autografts
Transplants
Multiple Myeloma
Lymphoma
Clinical Trials
Drug Therapy

Keywords

  • allogeneic transplant
  • autologous transplant
  • lymphoplasmacytic lymphoma
  • non-Hodgkin lymphoma
  • stem cell transplant
  • Waldenström macroglobulinemia

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Stem cell transplant for Waldenström macroglobulinemia : An underutilized technique. / Gertz, Morie; Reeder, C. B.; Kyle, R. A.; Ansell, Stephen Maxted.

In: Bone Marrow Transplantation, Vol. 47, No. 9, 09.2012, p. 1147-1153.

Research output: Contribution to journalArticle

@article{dc571c6bd90542af8c247f72af40f659,
title = "Stem cell transplant for Waldenstr{\"o}m macroglobulinemia: An underutilized technique",
abstract = "Waldenstr{\"o}m macroglobulinemia is a highly chemosensitive lymphoplasmacytic lymphoma with response rates of 90{\%} to first-line chemotherapy. The fraction of patients undergoing stem cell transplant for this disorder appears to be lower than that of patients with multiple myeloma. The indolent nature and favorable genetic profile should make Waldenstr{\"o}m an ideal disorder for autologous stem cell transplant, with high response rates that are durable. We review the literature on autologous and allogeneic transplants for Waldenstr{\"o}m macroglobulinemia and conclude that autologous transplant is effective and underutilized in the management of this disorder. Allogeneic transplant should be considered investigational and used only in the context of a clinical trial or when other chemotherapeutic options have been exhausted.",
keywords = "allogeneic transplant, autologous transplant, lymphoplasmacytic lymphoma, non-Hodgkin lymphoma, stem cell transplant, Waldenstr{\"o}m macroglobulinemia",
author = "Morie Gertz and Reeder, {C. B.} and Kyle, {R. A.} and Ansell, {Stephen Maxted}",
year = "2012",
month = "9",
doi = "10.1038/bmt.2011.175",
language = "English (US)",
volume = "47",
pages = "1147--1153",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Stem cell transplant for Waldenström macroglobulinemia

T2 - An underutilized technique

AU - Gertz, Morie

AU - Reeder, C. B.

AU - Kyle, R. A.

AU - Ansell, Stephen Maxted

PY - 2012/9

Y1 - 2012/9

N2 - Waldenström macroglobulinemia is a highly chemosensitive lymphoplasmacytic lymphoma with response rates of 90% to first-line chemotherapy. The fraction of patients undergoing stem cell transplant for this disorder appears to be lower than that of patients with multiple myeloma. The indolent nature and favorable genetic profile should make Waldenström an ideal disorder for autologous stem cell transplant, with high response rates that are durable. We review the literature on autologous and allogeneic transplants for Waldenström macroglobulinemia and conclude that autologous transplant is effective and underutilized in the management of this disorder. Allogeneic transplant should be considered investigational and used only in the context of a clinical trial or when other chemotherapeutic options have been exhausted.

AB - Waldenström macroglobulinemia is a highly chemosensitive lymphoplasmacytic lymphoma with response rates of 90% to first-line chemotherapy. The fraction of patients undergoing stem cell transplant for this disorder appears to be lower than that of patients with multiple myeloma. The indolent nature and favorable genetic profile should make Waldenström an ideal disorder for autologous stem cell transplant, with high response rates that are durable. We review the literature on autologous and allogeneic transplants for Waldenström macroglobulinemia and conclude that autologous transplant is effective and underutilized in the management of this disorder. Allogeneic transplant should be considered investigational and used only in the context of a clinical trial or when other chemotherapeutic options have been exhausted.

KW - allogeneic transplant

KW - autologous transplant

KW - lymphoplasmacytic lymphoma

KW - non-Hodgkin lymphoma

KW - stem cell transplant

KW - Waldenström macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=84865975384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865975384&partnerID=8YFLogxK

U2 - 10.1038/bmt.2011.175

DO - 10.1038/bmt.2011.175

M3 - Article

VL - 47

SP - 1147

EP - 1153

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -